Dr Reddys Laboratories (RDY) Net Margin (2009 - 2023)

Dr Reddys Laboratories (RDY) has reported Net Margin for 15 consecutive years, with 21.5% the latest figure, recorded in Q2 2023.

• Quarterly Net Margin changed N/A year-over-year to 21.5% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 0.0% (changed N/A YoY) and the FY2026 annual result came in at 12.74%, down 466.0% from the prior year.
• Net Margin improved to 21.5% in Q2 2023 per RDY's latest filing, from 20.84% in the prior quarter.
• Over the last five years, Net Margin for RDY reached as high as 22.73% in Q2 2019 and fell as low as 16.0% in Q3 2020.
• A 5-year average of 12.07% and a median of 17.25% in 2021 frame the typical range for Net Margin.
• The largest YoY upside for Net Margin was 957 bps in 2019 against a maximum downside of 2560 bps in 2019.
• Year by year, Net Margin stood at 13.03% in 2019, then slipped by 23 bps to 16.0% in 2020, then surged by 208 bps to 17.25% in 2021, then fell by 12 bps to 15.25% in 2022, then soared by 41 bps to 21.5% in 2023.
• According to Business Quant data, Net Margin over the past three periods registered 21.5%, 20.84%, and 15.25% for Q2 2023, Q1 2023, and Q4 2022 respectively.